Major Drugs Used in COVID-19 Treatment: Molecular Mechanisms, Validation and Current Progress in Trials

(E-pub Ahead of Print)

Author(s): Md. Asaduzzaman Khan*, Shad Bin Islam, Mejbah Uddin Rakib, Didarul Alam, Md. Munnaf Hossen, Mousumi Tania, Asaduzzaman Asad

Journal Name: Coronaviruses
The World's First International Journal Dedicated to Coronaviruses

Article ID: e030821188723
Become EABM
Become Reviewer
Call for Editor


Background: Currently, the present world is facing a new deadly challenge against a pandemic disease called COVID-19, which is caused by a coronavirus, named SARS-CoV-2. To date, there is no drug or vaccine that can treat COVID-19 completely, but some drugs have been used primarily, and they are in different stages of clinical trials. This review article discussed and compared those drugs which are running ahead in COVID-19 treatments.

Methods: We have explored PUBMED, SCOPUS, WEB OF SCIENCE, as well as press release of WHO, NIH and FDA for articles about COVID-19, and reviewed them.

Results: Drugs like favipiravir, remdesivir, lopinavir/ritonavir, hydroxychloroquine, azithromycin, ivermectin, corticosteroids and interferons have been found effective in some extents, and partially approved by FDA and WHO to treat COVID-19 at different phases of pandemic. However, some of these drugs have been disapproved later, although clinical trials are going on. In parallel, plasma therapy has been found fruitful in some extents too, and a number of vaccine trails are going on.

Conclusions: This review article discussed the epidemiologic and mechanistic characteristics of SARS-CoV-2, and how drugs could act on this virus with the comparative discussion on progress and backwards of major drugs used till date, which might be beneficial for choosing therapies against COVID-19 in different countries.

Keywords: Antiviral drugs, Clinical trials, COVID-19, Molecular mechanisms, Pandemic, SARS-CoV-2

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e030821188723
(E-pub Ahead of Print)
DOI: 10.2174/2666796701999201204122819

Article Metrics

PDF: 4